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Practical Guidelines for DNA-Based Testing in Multiple Endocrine
Neoplasia Type 1

Catharina Larsson,* Magnus Nordenskjold,* Britt Skogseid,^ and Kjell Oberg*

Multiple endocrine neoplasia type I (MEN I) is an autosomal dominant predisposition to neoplastic
lesions ofthe parathyroid glands, the neuroendocrine pancreas, and the anterior pituitary gland. The
predisposing genetic defect was localized to the long arm of chromosome 11 by genetic linkage
analysis in three affected families. By analyzing six MEN I families with 14 DNA marker systems
located close to the MEN I gene, we have developed a method to identify carriers of the MEN I
predisposition. We describe practical aspects of such DNA-based diagnostic procedures. (Henry
FordHospMedJ 1992;40:173-6]

I

t is generally believed that morbidity and mortality in neoplastic diseases may be reduced by prevention, early detection, and by identifying individuals "at increased risk." In multiple endocrine neoplasia type 1 (MEN 1) the two latter goals are
approached by offering biochemical screening programs to the
members of these families. Since the MEN 1 predisposition has
a genetic origin, the utilization of such screening programs is
largely dependent on factors such as mode of inheritance, penetrance, expression, and age of onset. The familial and genetic
nature of the disease was first pointed out by Wermer (1) in 1954
who suggested that an autosomal dominant gene with high penetrance controlled the trait. The clinical picture is variable, depending largely on the glands involved and whether or not the
lesions hypersecrete symptom-causing hormones. The parathyroid glands are most frequentiy involved, followed by the neuroendocrine pancreas and the anterior pituitary gland. It has
been shown that the age of diagnosis may be lowered by approximately two decades by screening (2). On the other hand, the reported ages of onset range from 6 to 81 years (3,4) which makes
it difficuh to exclude family members from being at risk. Thus,
children of unaffected family members at risk are sometimes
also included in the screening programs. Furthermore, the much
more common sporadic counterparts of MEN 1-associated neoplastic lesions may mimick the MEN 1 phenotype. Hence, the
diagnosis of the MEN 1 predisposition would benefit from a
method to detect carriers of the gene (MEN 1).

Methods for DNA Testing
Clinical cases
The five Swedish families with MEN 1 have been described
elsewhere (5,6). The sixth family is a large pedigree from Tasmania, first reported by Shepherd (7) in 1985 in which over 150
affected individuals from 2,300 family members spanning eight
generations had been traced back to a woman who came to Tasmania in the middle of the last century (8). The description of
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this patient recorded by the ship's surgeon is consistent with the
diagnosis of MEN 1.
The scoring for MEN 1 was conservative in order to avoid incorrect diagnoses. Unaffected individuals at risk were scored as
"normal" only if they had passed the age of 35 years and had undergone repeated and extensive biochemical screenings (2) with
no signs of the disease, while offspring of MEN 1 cases who did
not fulfill these criteria were scored as "unknown."
DNA probes and Southern analysis
A set of DNA probes suitable for DNA testing is described
in the Table. D l lS288/pTHH26, Dl lS149/p3C7, PYGM/
pMCMPl, and DllS146/pHB159 are available from ATCC.
CD20 was obtained from T. F. Tedder, pcAGP9/PGA from B.
Zelle, DllS97/pMS51 from ICI, INT2/SS6 from N. Spurr,
clone 8/Dl 1S751 from T. Rabbits, and the newly isolated cosmid clones for D11S480, D11S427, and D11S449 from Y.
Nakamura. New allele systems were identified through locus
expansion in cosmids for PGA (cCLPGA12), PYGM (cCL15),
D11S146 (cCL59), and DllS751/clone 8 (cCL8). Two new
cosmid clones, Dl lS750/cCLGW4 and D l lS807/cCLGW39,
were isolated from a library constructed from radiation-reduced
somatic cell hybrids containing the 1 Iql2-ql3 region (9).
Three marker systems (D11S146, Dl 1S751, and INT2) with
two separate 2-allele restriction fragment length polymorphisms (RFLPs) can be combined to 4-allele systems by haplotyping. The markers Dl 1S288 and Dl IS 149 can also be combined by haplotyping to increase their relative information con-
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Table
DNA Markers Linked to the MEN 1 Locus
Locus
Name

Probe
Name

Enzyme

Constant
Bands

D11S288
D11S149

p3C7
pTHH26

Mspl
PvuII

CD20

pBl-2I

Mspl

2.8

cCIlI-319®

Pstl

several

D1IS480
PGA

pcAGP9

EcoRl

CCLPGAI2®

PvuII

several

pMCMPI®
cCL15®

Mspl
EcoRl

14; 6.6; 5.4

DIIS427
D11S750

cCIII-4®
CCLGW4®

EcoRl
Sad

21; 16
several

DIIS807

CCLGW39®

Sad

several

D11S449

cCIII-219®

PvuII

several

D11S97
DUS 146

pMS51
pHBI59

Hadll/TaqI
TaqI

cCL59®

EcoRV

24; 18; 74

cCL-8®

EcoRV

20; 5.2; 2.2

Sad

16; 12; 4; 3

PYGM

DIIS75I

clone 8
INT2

SS6

EcoRl
TaqI
BamHI

Allele
Sizes(kb)
5.7
3.1
5.2
3.2
y.o
A.O
3.0
1.4
19.0
16.6-I-15-H3.5
I6,6-i-15-hI2-i-3.5
11
6-H5
2.2-2.5
19.0
17.5
9.0 - 9.6
3.6
2.4
s.4
4..S
37
3.0
1.3-4.3
1.2
0.8
7.1)
(-.4
6,6
5,8
10,0
9.2
7.4
6.7
4.1
2.3
84
5.6-1-2.8

Allele
Fi-equency
0,72
0,28
0,14
0.84
0,47
0,53
0.50
0.50
0.06
0.37
0.54
0.37
0.63
5 alleles
0,11
0,89
4 alleles
0.80
0.20
0.70
0.30
0,33
0.67
9 alleles
0.55
0.45
0,22
0.78
0.50
0,50
0..50
0.50
0.89
0.11
0.60
0.40
0.63
0.37

Electi-ophoresis*
(% agarose, length)

0,5-0.6%, 30 cm
1.1%, 30 cm
0.6%, 20-30 cm
0.5-0.6%, 30 cm

0,9%, 20 cm
l%.20cm

0.9%, 20 cm
0.8%, 20 cm
0.8%, 20 cm
0.6%, 20-30 cm

*Electrophoresis conditions are only indicated when special conditions are needed.
Note: Loci in bold indicate "anchor markers" previously mapped on reference families. Loci in italics indicate those located closest to the MEN 1 gene.
>) indicates probes with repetitive elements for which human DNA was included in the hybridization.

tent. Haplotyping of the two markers for the PYGM locus and
the combined D11S97 + DIIS 146 markers is also possible
since these markers are closely linked. Details for isolation and
restriction enzyme cleavage of DNA, Southem analysis, and hybridization to radioactively-labeled probes have been described
(10).

Discussion
Localization of the MEN 1 gene to chromosomal region
llqll-ql3
Localization of tumor predisposing genes has been facilitated
in several conditions such as retinoblastoma and familial polyposis coli by identification of constitutional chromosomal aberrations. This has not been possible in MEN 1. Our working hypothesis was that MEN 1-associated tumors may result from unmasking of a recessive mutation according to the two-mutation
model originally postulated by Knudson (11). Genetic rear-
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rangements in such tumors would indicate on which chromosome MENl is situated. Such rearrangements would be expected in all tumor cells, restricted to a specific chromosome
(12), and would serve to eliminate the wild type allele of MEN 1.
We compared constitutional and tumor genotypes at different
chromosomal loci in two brothers with insulinomas who had inherited the disease from their mother (5). Markers on 17 chromosomes showed retained genotypes, but both tumors had lost
one ofthe constitutional alleles at all informative loci on chromosome 11. Combined pedigree and genotype analysis revealed that the lost alleles were always derived from the unaffected father (5). Thesefindingsfit the hypothesis that the tumors resulted from elimination of the two MENl alleles (13).
Subsequentiy, the tentative localization was confirmed by demonstration of linkage between MEN 1 and the PYGM locus at
1 lql3 in three families (5). No meiotic recombinations were observed and the odds in favor of linkage were lO"*-^^: 1, which is
well above the level of significance accepted for linkage analy-
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sis. The localization was later confirmed in four other families
(14,15).
The linkage map around the MENl locus (16,17) includes 7
polymorphic "anchor markers" covering approximately 12 cM;
l l p - (D11S149-D11S288) -PGA-PYGM- (Dl 1S97-D11S146INT2). These markers were analyzed in five families and meiotic crossovers were identified for markers at both ends of this
region (16).
Panel of polymorphic DNA markers
We then attempted to develop a reliable and accurate DNAbased diagnostic procedure for the MEN 1 predisposition (6).
To be of clinical use such procedures should fulfill the following
criteria:
1. Meiotic crossing-over between the disease and the marker
loci must be rare and should be detectable. This can be achieved
by using markers close to, as well as flanking, the locus on both
sides.
2. Incorrect diagnosis of an individual, nonpaternity, or mixing of samples are possible causes of incorrect results from
DNA-based testing of inherited diseases. Nonpaternity or sample mixups can sometimes be recognized if several markers are
used in the linkage analysis.
DNA-based testing procedures can make use of the detailed
genetic mapping data recently generated for the chromosomal
region llqll-13 (9,18,19). This involved isolation of new genetic markers which have been mapped physically utilizing somatic cell hybrids or pulsed-field gel electrophoresis. Using different polymorphic DNA markers, we genotyped 124 members
of six MEN 1 families, including 59 affected individuals, and
determined the genetic linkage between MENl and these
marker systems (6). Fourteen marker systems (18 DNA probes)
were found to be linked to MENl. Four of the marker systems
were on the centromeric side of MENl while the others were either telomeric or close to MENl. The markers, their alleles, and
experimental conditions are listed in the Table. The order from
centromere (top) to telomere is based on combined data from
linkage and physical mapping (9,16-19) and the markers closest
to MENl are italicized (Table).
DNA-based diagnosis of MEN 1
DNA-based predictive testing for MEN 1 utilizes markers located close to the disease gene on chromosome 11. In a kindred
with at least two affected members it is possible to follow the
disease gene by the segregation of the marker alleles thereby
identifying the haplotype for this chromosomal region carrying
the MENl mutation. In most clinical situations, it is possible to
identify a haplotype with the mutant MEN 1 allele in the middle
ifthe described set of markers is used (Figure). With two fianking marker systems informative, the calculated predicted accuracy would be greater than 99.5%. The practical considerations
of such DNA-based testing are described in the following examples:
1. A large family where several members can be genotyped:
This is the "easiest" situation, where the family alone is large
enough to show linkage between MEN 1 and the RFLP markers.
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PGA -pcAGPg
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D11S97

2
1
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4 ^
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3
2
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1
3
1

Figure—Pedigree illustrating DNA-based predictive testing for
MEN 1. Filled .symbols indicate affected family members. Numbers below each individual indicate the genotypes for the informative marker systems listed next to the symbol of the carrier
parent. The haplotypes for each individual are depicted along
an illustrated chromosome segment with the inferred mutant
chromosome indicated hy a thin line and the wild type chromosome of the carrier parent hatched. As illustrated, the two
younger children have not shown any signs of MEN 1. The haplotypes illustrate that the first daughter (II-l) and the brother
(II-4, age 25) can-y the disease gene, while the second (11-2, age
36) and third daughters (11-3, age 26) are not gene carriers.

2. A family where only a few persons can be genotyped:
There is a theoretical possibility of genetic heterogeneity between MEN 1 families which could be overlooked in this type of
family. This issue will be clarified by genetic analysis of additional MEN 1 families although the disease gene has been linked
to 1 lql3 in all 11 reported families (5,6,14-16).
3. A family where only one affected individual can be analyzed: Generally, linkage analysis can only be applied when the
haplotypes of at least two affected individuals can be compared.
However, allele losses in MEN 1-associated pancreatic and
parathyroid tumors serve to eliminate the wild type allele (5,20).
Tumor studies could therefore be used to identify which haplotype carries the mutated MEN 1 allele. However, pituitary and
adrenocortical tumors could not be used for this purpose since
the former are rarely operated on in MEN 1 patients and the latter have not shown allele losses for chromosome 11 markers
(21).
4. A single patient with MEN 1 syndrome: This patient most
certainly has a constitutional predisposition to MEN 1. However, the mutational event may be prezygotic or postzygotic,
and in the last situation it is not necessarily heritable. Hence, the
offspring may all be without risk of developing MEN 1.
5. A famdy with an "MEN 1-related" clinical picture: Again,
the possibility of genetic heterogeneity must be taken into account.
DNA-based diagnosis and biochemical screening provide a
tool to detect individuals at risk of developing MEN 1 and to
identify the neoplastic lesion at an early stage. A future goal will
be to use these tools to decrease morbidity and mortality in
MEN 1.
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